Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cerevel Therapeutics Holdings (CERE)
NASDAQ:CERE
RESEARCH TOOLSreports
Holding CERE?
Track your performance easily
CERE Stock Chart & Stats
Day’s Range$44.96 - $44.99
52-Week Range― - ―
Previous Close$44.63
Volume15.10M
Average Volume (3M)N/A
Market Cap
$8.19B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$45.00Price Target Upside0.09% Upside
Rating ConsensusHold
Number of Analyst Covering1
Cerevel Therapeutics Holdings News
PremiumCompany Announcements
Cerevel Therapeutics’ Corporate Transformation and Market Delisting
Bulls Say, Bears Say
Bulls Say
AcquisitionCERE's pending acquisition by ABBV is expected to close, indicating confidence in the deal's completion.
Clinical TrialsCERE announced positive Phase 3 TEMPO-3 study data for tavapadon, a treatment for Parkinson's disease, meeting its primary endpoint and showing a significant increase in 'on' time without troublesome dyskinesia.
Financial PerformanceCERE's share price is currently trading below the acquisition price, suggesting a potential upside if the transaction is completed as planned.
Bears Say
Merger DelayThe FTC's Second Request for additional information on the CERE-ABBV merger extends the waiting period, potentially delaying the deal.
Revenue ContributorTavapadon represents a relatively small revenue contributor to CERE's pipeline efforts.
Stock Price CapThe proposed acquisition of CERE by AbbVie is likely to keep the stock price capped at the December 2023 acquisition offer price, leading to a Neutral rating on CERE.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CERE FAQ
What was Cerevel Therapeutics Holdings’s price range in the past 12 months?
Currently, no data Available
What is Cerevel Therapeutics Holdings’s market cap?
Currently, no data Available
When is Cerevel Therapeutics Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cerevel Therapeutics Holdings’s earnings last quarter?
Currently, no data Available
Is Cerevel Therapeutics Holdings overvalued?
According to Wall Street analysts Cerevel Therapeutics Holdings’s price is currently Undervalued.
Does Cerevel Therapeutics Holdings pay dividends?
Cerevel Therapeutics Holdings does not currently pay dividends.
What is Cerevel Therapeutics Holdings’s EPS estimate?
Cerevel Therapeutics Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cerevel Therapeutics Holdings have?
Currently, no data Available
What happened to Cerevel Therapeutics Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cerevel Therapeutics Holdings?
Among the largest hedge funds holding Cerevel Therapeutics Holdings’s share is Perceptive Advisors LLC. It holds Cerevel Therapeutics Holdings’s shares valued at 456M.
---
Cerevel Therapeutics Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$45.00 (0.09% Upside)
$45.00 (0.09% Upside)
Blogger Sentiment
Bullish
CERE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.08%
12-Months-Change
Fundamentals
Return on Equity
-92.45%
Trailing 12-Months
Asset Growth
21.17%
Trailing 12-Months
Company Description
Cerevel Therapeutics Holdings
ARYA Sciences Acquisition Corp II is a blank check company.
---
CERE Stock 12 Month Forecast
Average Price Target
$45.00
▲(0.09% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Akebia Therapeutics
―
Avadel Pharmaceuticals
―
Blueprint Medicines
―
Best Analysts Covering CERE
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+42.28%
reiterated a buy rating a year ago
Copying Matthew Harrison's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +42.28% per trade.
---